Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection

Kristian Thorlund1 Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton

Eric Druyts2 Faculty of Health Sciences, University of Ottawa, Ottawa, Ontario, Canada

Antoine C El Khoury3 Merck Sharp and Dohme, Whitehouse Station, NJ, USA

Edward J Mills2 Faculty of Health Sciences, University of Ottawa, Ottawa, Ontario, CanadaCorrespondence[email protected]

Pages 349-359 | Published online: 16 Nov 2012

Cite this article

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

CooperCDruytsEThorlundKBoceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysisTher Clin Risk Manag2012810513022442631
PubMed Web of Science ®Google Scholar
PoordadFKhungarVEmerging therapeutic options in hepatitis C virus infectionAm J Manag Care201117 Suppl 4S123S13021767068
PubMed Web of Science ®Google Scholar
HofmannWPZeuzemSA new standard of care for the treatment of chronic HCV infectionNat Rev Gastroenterol Hepatol2011825726421468124
PubMed Web of Science ®Google Scholar
CiesekSMannsMPHepatitis in 2010: the dawn of a new era in HCV therapyNat Rev Gastroenterol Hepatol20118697121293503
PubMed Web of Science ®Google Scholar
CooperCLesterRThorlundKDirect-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysisQJM2012In press
Web of Science ®Google Scholar
NelsonDJensenDSulkowskiMHCV clinical management resource2011 Available from: img.medscape.com/article/746/388/HCV_746388.pdfAccessed October 8, 2012
Google Scholar
PoordadFMcConeJBaconBBoceprevir for untreated chronic HCV genotype 1 InfectionN Engl J Med2011364131195120621449783
PubMed Web of Science ®Google Scholar
BaconBRGordonSCLawitzEBoceprevir for previously treated chronic HCV genotype 1 infectionN Engl J Med2011364131207121721449784
PubMed Web of Science ®Google Scholar
JacobsonIMMcHutchisonJGDusheikoGTelaprevir for previously untreated chronic hepatitis C virus infectionN Engl J Med2011364252405241621696307
PubMed Web of Science ®Google Scholar
KumadaHToyotaJOkanoueTChayamaKTsubouchiHHayashiNTelaprevir with PEGinterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in JapanJ Hepatol2011561788421827730
PubMed Web of Science ®Google Scholar
HezodeCForestierNDusheikoGTelaprevir and PEGinterferon with or without ribavirin for chronic HCV infectionN Engl J Med2009360181839185019403903
PubMed Web of Science ®Google Scholar
McHutchisonJGEversonGTGordonSCTelaprevir with PEGinterferon and ribavirin for chronic HCV genotype 1 infectionN Engl J Med2009360181827183819403902
PubMed Web of Science ®Google Scholar
McHutchisonJGMannsMPMuirAJTelaprevir for previously treated chronic HCV infectionN Engl J Med2010362141292130320375406
PubMed Web of Science ®Google Scholar
ZeuzemSAndreonePPolSTelaprevir for retreatment of HCV infectionN Engl J Med2011364252417242821696308
PubMed Web of Science ®Google Scholar
MIMSMIMS: Prescription drug database and drug prescribing guide2012 Available at: http://www.mims.co.uk/
Google Scholar
ShermanKFlammSAfdhalNResponse-guided telaprevir combination treatment for hepatitis C virus infectionN Engl J Med2011365111014102421916639
PubMed Web of Science ®Google Scholar
MarcellinPFornsXGoeserTTelaprevir is effective given every 8 or 12 hours with ribavirin and PEGinterferon alfa-2a or-2b to patients with chronic hepatitis CGastroenterology2011140245921034744
PubMed Web of Science ®Google Scholar
DruytsEMillsENachegaJO’ReganCCooperCDifferences in clinical outcomes among hepatitis C genotype 1-infected patients treated with PEGinterferon alpha-2a or PEGinterferon alpha-2b plus ribavirin: a meta-analysisClin Exp Gastroenterol20125112122427726
PubMedGoogle Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date